V. N. Bodnya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
V. N. Bodnya has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Anastasiya I. Stukan
Kuban State Medical University, Ministry of Health of Russia
12 shared publications - Vladimir Alekseyevich Porkhanov
Scientific Research Institute – Ochapovsky Regional Clinical Hospital no. 1; Kuban State Medical University
11 shared publications - Tatiana Yurievna Semiglazova
N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia
4 shared publications - A. Yu. Georgieva
Kuban State Medical University
3 shared publications - E. A. Nefyodova
Clinical Oncologic Dispensary No. 1
3 shared publications O. Yu. Chukhray
Clinical Oncological Dispensary No. 1, Ministry of Health of the Krasnodar Territory
3 shared publications
Latest Publications
- 29 June 2026
- Published by "MedINK" Publishing House in Academy for Practical Oncology
- Vol. 1 (1)
Adenocystic cancer of minor salivary glands: peculiarities of clinical course
Adenoid cystic carcinoma of the minor salivary glands is a rare and aggressive form of malignant neoplasms characterized by hidden growth, rapid perineural advancement, tendency to develop local recurrences and distant metastases. This pathology is mostly seen in white women aged 50–60 years and is mostly localized in the sinonasal area and oral cavity. The article presents clinical cases of treatment of patients with adenoid cystic carcinoma of the sinonasal area and adenoid cystic carcinoma of the hard palate. Efficacy of off-label therapy as salvage therapy and an attempt to prolong life in incurable patients is demonstrated. Etiopathogenesis of this tumor is being investigated, and new treatment strategies are being developed, including targeted therapies.
- 29 June 2026
- Published by "MedINK" Publishing House in Academy for Practical Oncology
- Vol. 1 (1)
Adenocystic cancer of minor salivary glands: peculiarities of clinical course
Adenoid cystic carcinoma of the minor salivary glands is a rare and aggressive form of malignant neoplasms characterized by hidden growth, rapid perineural advancement, tendency to develop local recurrences and distant metastases. This pathology is mostly seen in white women aged 50–60 years and is mostly localized in the sinonasal area and oral cavity. The article presents clinical cases of treatment of patients with adenoid cystic carcinoma of the sinonasal area and adenoid cystic carcinoma of the hard palate. Efficacy of off-label therapy as salvage therapy and an attempt to prolong life in incurable patients is demonstrated. Etiopathogenesis of this tumor is being investigated, and new treatment strategies are being developed, including targeted therapies.
- Open Access
- 1 January 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 21,p. 60-66
Efficacy of targeted therapy in advanced NSCLC patients with rare EGFR mutations and combinations of mutations
The efficacy of targeted therapy in rare epidermal growth factor receptor ( EGFR ) gene mutations in non-small cell lung cancer is debatable. However, due to introduction of NGS technology into clinical practice, patients with non-small cell lung cancer (NSCLC) harbouring rare EGFR mutations are being identified more often. We report here the case demonstrating the absence of EGFR mutations at the initial stage of diagnosis of metastatic lung adenocarcinoma in November 2024. The chemotherapy consisting of pemetrexed, carboplatin, and bevacizumab was initiated in December 2024. During treatment, a comprehensive genomic profiling test (Foundation One Liquid CDx Roche) was performed to evaluate a patient’s blood for circulating tumour DNA (ctDNA). A rare EGFR E114K extracellular domain mutation and mutations in the cell cycle checkpoint kinase 2 ( CHEK2 ) – V335fs*14, PTPN11 – G503V, and TP53 splice site 375G > T were identified. Osimertinib at a dose of 80 mg daily has been administered since April 2025. After the sixth course of polychemotherapy and targeted therapy (PCT+TT) in May 2025 and with due account for stabilization based on 18F-FDG PET-CT findings, the patient continued to receive the maintenance chemotargeted therapy with pemetrexed and osimertinib, showing disease stability. Most studies that led to the introduction of tyrosine kinase inhibitors excluded patients with rare EGFR mutations. Moreover, for many mutations, it is still unclear whether they are disease activating or merely incidental findings. Nevertheless, the available separate data suggest that osimertinib, EGFR tyrosine kinase inhibitor (EGFR-TKI), has clinical efficacy in rare EGFR mutations.
- 1 January 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 21,p. 60-66
Open AccessEfficacy of targeted therapy in advanced NSCLC patients with rare EGFR mutations and combinations of mutations
The efficacy of targeted therapy in rare epidermal growth factor receptor ( EGFR ) gene mutations in non-small cell lung cancer is debatable. However, due to introduction of NGS technology into clinical practice, patients with non-small cell lung cancer (NSCLC) harbouring rare EGFR mutations are being identified more often. We report here the case demonstrating the absence of EGFR mutations at the initial stage of diagnosis of metastatic lung adenocarcinoma in November 2024. The chemotherapy consisting of pemetrexed, carboplatin, and bevacizumab was initiated in December 2024. During treatment, a comprehensive genomic profiling test (Foundation One Liquid CDx Roche) was performed to evaluate a patient’s blood for circulating tumour DNA (ctDNA). A rare EGFR E114K extracellular domain mutation and mutations in the cell cycle checkpoint kinase 2 ( CHEK2 ) – V335fs*14, PTPN11 – G503V, and TP53 splice site 375G > T were identified. Osimertinib at a dose of 80 mg daily has been administered since April 2025. After the sixth course of polychemotherapy and targeted therapy (PCT+TT) in May 2025 and with due account for stabilization based on 18F-FDG PET-CT findings, the patient continued to receive the maintenance chemotargeted therapy with pemetrexed and osimertinib, showing disease stability. Most studies that led to the introduction of tyrosine kinase inhibitors excluded patients with rare EGFR mutations. Moreover, for many mutations, it is still unclear whether they are disease activating or merely incidental findings. Nevertheless, the available separate data suggest that osimertinib, EGFR tyrosine kinase inhibitor (EGFR-TKI), has clinical efficacy in rare EGFR mutations.
- Open Access
- 30 August 2025
- Published by Scientific Research Institute - Ochapovsky Regional Clinical Hospital No 1 in Innovative Medicine of Kuban
- Vol. 10 (3) , 23-29
Prognostic Significance of Cancer Stem Cell Markers and Tumor Microenvironment Components for Assessing the Efficacy of Chemoradiotherapy in Patients with Locally Advanced rectal cancer
Background: Despite the incorporation of neoadjuvant chemoradiotherapy into the standard treatment of locally advanced rectal cancer, significant variability in therapeutic response persists. This highlights the need for patient stratification using prognostic biomarkers. The identification of reliable morphological and immunohistochemical predictors of tumor resistance may enhance the effectiveness of personalized treatment strategies.Objective: To assess the prognostic value of cancer stem cell markers and components of the tumor microenvironment in predicting response to chemoradiotherapy in patients with locally advanced rectal cancer.Materials and Methods: The study included histological blocks obtained from biopsy and postoperative speciments of 75 patients with histoligically confirmed rectal adenocarcinoma who had undergone neoadjuvant chemoradiotherapy. Tumor regression grade (TRG) and immunohistochemical expression of ALDH1, TWIST, CD44, E-cadherin, LAG3, and CD20 were evaluated. Cut-off values were determined using ROC analysis. Associations between marker expression, clinicopathologic features, and treatment response were assessed. Results: A statistically significant association was found between poor response to chemoradiotherapy (TRG 2–3) and high expression of the following markers: ALDH1 >20% in 78.4% of patients (vs 26.3% in the TRG 0–1 group), TWIST >15% in 73.0% (vs 31.6%), CD44 >25% in 64.9% (vs 23.7%), LAG3 >10% in 64.9% (vs 28.9%), and CD20 >25% in 62.2% (vs 21.1%). Reduced E-cadherin expression (Conclusions: Assessment of the expression levels of the pathomorphological markers ALDH1, TWIST, CD44, E-cadherin, LAG3, and CD20 represents a significant prognostic indicator of tumor response to chemoradiotherapy. Integration of a comprehensive evaluation algorithm may facilitate personalize treatment strategies for patients with locally advanced rectal cancer.
- 30 August 2025
- Published by Scientific Research Institute - Ochapovsky Regional Clinical Hospital No 1 in Innovative Medicine of Kuban
- Vol. 10 (3) , 23-29
Open AccessPrognostic Significance of Cancer Stem Cell Markers and Tumor Microenvironment Components for Assessing the Efficacy of Chemoradiotherapy in Patients with Locally Advanced rectal cancer
Background: Despite the incorporation of neoadjuvant chemoradiotherapy into the standard treatment of locally advanced rectal cancer, significant variability in therapeutic response persists. This highlights the need for patient stratification using prognostic biomarkers. The identification of reliable morphological and immunohistochemical predictors of tumor resistance may enhance the effectiveness of personalized treatment strategies.Objective: To assess the prognostic value of cancer stem cell markers and components of the tumor microenvironment in predicting response to chemoradiotherapy in patients with locally advanced rectal cancer.Materials and Methods: The study included histological blocks obtained from biopsy and postoperative speciments of 75 patients with histoligically confirmed rectal adenocarcinoma who had undergone neoadjuvant chemoradiotherapy. Tumor regression grade (TRG) and immunohistochemical expression of ALDH1, TWIST, CD44, E-cadherin, LAG3, and CD20 were evaluated. Cut-off values were determined using ROC analysis. Associations between marker expression, clinicopathologic features, and treatment response were assessed. Results: A statistically significant association was found between poor response to chemoradiotherapy (TRG 2–3) and high expression of the following markers: ALDH1 >20% in 78.4% of patients (vs 26.3% in the TRG 0–1 group), TWIST >15% in 73.0% (vs 31.6%), CD44 >25% in 64.9% (vs 23.7%), LAG3 >10% in 64.9% (vs 28.9%), and CD20 >25% in 62.2% (vs 21.1%). Reduced E-cadherin expression (Conclusions: Assessment of the expression levels of the pathomorphological markers ALDH1, TWIST, CD44, E-cadherin, LAG3, and CD20 represents a significant prognostic indicator of tumor response to chemoradiotherapy. Integration of a comprehensive evaluation algorithm may facilitate personalize treatment strategies for patients with locally advanced rectal cancer.
- Open Access
- 6 August 2025
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 21 (2) , 104-118
HRR gene mutations and characteristics of the tumor microenvironment as predictors of response to olaparib therapy in metastatic castration-resistant prostate cancer
Aim. To identify clinical, molecular, genetic, and immunological predictors of response to PARP inhibitor olaparib therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) harboring germline and somatic mutations in homologous recombination repair (HRR) genes.Materials and methods. A prospective analysis was conducted on data from 39 patients with mCRPC and HRR gene mutations (BRCA1/2, ATM, CHEK2, CDK12, among others) receiving оlaparib therapy after prior treatment with androgen receptor signaling inhibitors. Diagnoses were histologically verified according to the current WHO classification (5th edition). Genetic status was determined by next-generation sequencing (NGS). The tumor immune microenvironment was evaluated by immunohistochemical analysis assessing expression of CD4, CD8, CD68, CD163 markers and tumor-infiltrating lymphocyte (TILs) levels. Statistical analysis involved Cox proportional-hazards regression and Kaplan–Meier survival analysis.Results. The BRCA2 mutation was the most frequently detected alteration (61 %), correlating with increased expression of CD163 and decreased CD68 expression. The most significant clinical predictors associated with improved progressionfree survival during оlaparib therapy included BRCA2 mutation positivity, patient age under 64 years, initially metastatic disease presentation, and ≥90 % reduction in prostate-specific antigen levels at 3 months post-treatment initiation. Immunological markers indicative of favorable therapeutic response included elevated levels of M2-polarized macrophages (CD163 ≥30 %) and a high CD163/CD68 ratio (≥2.83). Conversely, robust prior response to еnzalutamide therapy and administration of docetaxel during hormone-sensitive stages significantly worsened the prognosis for olaparib efficacy.Conclusion. Olaparib therapy is effective in patients with HRRm mCRPC, with particularly effectiveness in BRCA2m tumors. Clinical (age, disease dissemination pattern, prostate-specific antigen dynamics), immunological (CD163 expression and CD163/CD68 ratio), and molecular and genetic tumor characteristics should be considered when selecting patients for olaparib treatment, enhancing personalized therapeutic strategies in mCRPC management.
- 6 August 2025
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 21 (2) , 104-118
Open AccessHRR gene mutations and characteristics of the tumor microenvironment as predictors of response to olaparib therapy in metastatic castration-resistant prostate cancer
Aim. To identify clinical, molecular, genetic, and immunological predictors of response to PARP inhibitor olaparib therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) harboring germline and somatic mutations in homologous recombination repair (HRR) genes.Materials and methods. A prospective analysis was conducted on data from 39 patients with mCRPC and HRR gene mutations (BRCA1/2, ATM, CHEK2, CDK12, among others) receiving оlaparib therapy after prior treatment with androgen receptor signaling inhibitors. Diagnoses were histologically verified according to the current WHO classification (5th edition). Genetic status was determined by next-generation sequencing (NGS). The tumor immune microenvironment was evaluated by immunohistochemical analysis assessing expression of CD4, CD8, CD68, CD163 markers and tumor-infiltrating lymphocyte (TILs) levels. Statistical analysis involved Cox proportional-hazards regression and Kaplan–Meier survival analysis.Results. The BRCA2 mutation was the most frequently detected alteration (61 %), correlating with increased expression of CD163 and decreased CD68 expression. The most significant clinical predictors associated with improved progressionfree survival during оlaparib therapy included BRCA2 mutation positivity, patient age under 64 years, initially metastatic disease presentation, and ≥90 % reduction in prostate-specific antigen levels at 3 months post-treatment initiation. Immunological markers indicative of favorable therapeutic response included elevated levels of M2-polarized macrophages (CD163 ≥30 %) and a high CD163/CD68 ratio (≥2.83). Conversely, robust prior response to еnzalutamide therapy and administration of docetaxel during hormone-sensitive stages significantly worsened the prognosis for olaparib efficacy.Conclusion. Olaparib therapy is effective in patients with HRRm mCRPC, with particularly effectiveness in BRCA2m tumors. Clinical (age, disease dissemination pattern, prostate-specific antigen dynamics), immunological (CD163 expression and CD163/CD68 ratio), and molecular and genetic tumor characteristics should be considered when selecting patients for olaparib treatment, enhancing personalized therapeutic strategies in mCRPC management.
- Open Access
- 27 June 2024
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 14 (1) , 16-30
Chemotherapy with cetuximab in head and neck squamous cell carcinoma: immunological aspects and markers of treatment effectiveness in clinical practice
Introduction. Chemotherapy in combination with targeted therapy (CT + TT) using a monoclonal antibody against epidermal growth factor receptor (EGFR) cetuximab and subsequent maintenance targeted therapy (CT + TT/TT) is the leading 1st line therapy of recurrent/metastatic head and neck squamous cell carcinoma to achieve objective response irrespective of programmed cell death-ligand 1 (pD-L1) expression level. However, often in clinical practice patient profile does not match characteristics of patients included in registration studies. Therapy selection is based on massive advancement of the tumor, low performance status of the patient, use of various chemotherapy regimes which often decreases therapy effectiveness. This creates a necessity of identification of clinical markers of effectiveness based on the drug's pharmacodynamics and mechanism of action.Aim. To analyze the effect of clinical characteristics, peripheral blood markers, and systemic inflammation on long-term results of CT + TT/TT with cetuximab in cancer of the mucosa of the head and neck.Materials and methods. The prospective observational study performed at the Oncology Department with a course on thoracic surgery of the Kuban State Medical University, included 52 patients with head and neck squamous cell carcinoma receiving CT + TT/TT between 2020 and 2023. Clinical characteristics and results of peripheral blood tests were retrospectively analyzed, indices of inflammatory reaction prior to treatment and 12-16 weeks after CT + TT/TT with cetuximab were calculated. Statistical analysis was performed using the med Calc ver. 20.218 and IBM SPSS Statistics 22 software.Results. CT + TT/TT with cetuximab significantly increased red blood cell count (RBC), lymphocyte-monocyte ratio (LMR), and decreased systemic inflammatory markers (SIM) (p 0.05) 12-16 weeks after the start of treatment. Statistically significant decrease in progression-free survival for baseline RBC 3.9 x 1012/L (area under the ROC-curve, AUC) = 0.780; 95 % confidence interval (CI) 0.616-0.944; p = 0.0008), RBC ≤3.8 x 1012/L 12-16 weeks after the start of therapy (AUC = 0.748; 95 % CI 0.554-0.941; p = 0.0120) was observed. Survival was negatively affected by LMR 3.27 after 12-16 weeks of therapy (AUC = 0.685; 95 % CI 0.486-0.885; p = 0.0691). median survival of patients after the start of CT + TT/TT with cetuximab was 28 months (95 % CI 17-48), progression-free survival was 8 months (95 % CI 5-36). For RBC count 3.8 x 1012/L 12-16 weeks after the start of therapy, risk of progression decreased by 79 % (hazard ratio 0.21; 95 % CI 0.07-0.62; p = 0.0047). Partial response after 12-16 weeks of CT + TT/TT decreased progression risk more than 4-fold (p 0.05). The model decreasing progression-free survival includes baseline RBC ≤3.9 x 109/L, RBC ≤3.8 x 109/L after 12-16 weeks of CT + TT/TT with cetuximab and absence of partial response per the Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) (AUC = 0.792; 95 % CI 0.706-0.877; p = 0.0079).Conclusion. for prediction of CT + TT/TT with cetuximab effectiveness in patients with head and neck squamous cell carcinoma, baseline characteristics of the peripheral blood and systemic inflammation can be used. Additionally, correlations between these characteristics 12-16 weeks after the start of therapy and treatment effectiveness were observed. Increased RBC as an anemia marker can be considered an indirect mechanism of EGFR signaling pathway blocking by cetuximab through decreased level of interleukin 6, marker of systemic inflammation, and factor of chronic disease anemias hepcidin. In patients with head and neck squamous cell carcinoma, maximal effectiveness of CT + TT/TT with cetuximab requires not only therapy personalization but also anemia correction.
- 27 June 2024
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 14 (1) , 16-30
Open AccessChemotherapy with cetuximab in head and neck squamous cell carcinoma: immunological aspects and markers of treatment effectiveness in clinical practice
Introduction. Chemotherapy in combination with targeted therapy (CT + TT) using a monoclonal antibody against epidermal growth factor receptor (EGFR) cetuximab and subsequent maintenance targeted therapy (CT + TT/TT) is the leading 1st line therapy of recurrent/metastatic head and neck squamous cell carcinoma to achieve objective response irrespective of programmed cell death-ligand 1 (pD-L1) expression level. However, often in clinical practice patient profile does not match characteristics of patients included in registration studies. Therapy selection is based on massive advancement of the tumor, low performance status of the patient, use of various chemotherapy regimes which often decreases therapy effectiveness. This creates a necessity of identification of clinical markers of effectiveness based on the drug's pharmacodynamics and mechanism of action.Aim. To analyze the effect of clinical characteristics, peripheral blood markers, and systemic inflammation on long-term results of CT + TT/TT with cetuximab in cancer of the mucosa of the head and neck.Materials and methods. The prospective observational study performed at the Oncology Department with a course on thoracic surgery of the Kuban State Medical University, included 52 patients with head and neck squamous cell carcinoma receiving CT + TT/TT between 2020 and 2023. Clinical characteristics and results of peripheral blood tests were retrospectively analyzed, indices of inflammatory reaction prior to treatment and 12-16 weeks after CT + TT/TT with cetuximab were calculated. Statistical analysis was performed using the med Calc ver. 20.218 and IBM SPSS Statistics 22 software.Results. CT + TT/TT with cetuximab significantly increased red blood cell count (RBC), lymphocyte-monocyte ratio (LMR), and decreased systemic inflammatory markers (SIM) (p 0.05) 12-16 weeks after the start of treatment. Statistically significant decrease in progression-free survival for baseline RBC 3.9 x 1012/L (area under the ROC-curve, AUC) = 0.780; 95 % confidence interval (CI) 0.616-0.944; p = 0.0008), RBC ≤3.8 x 1012/L 12-16 weeks after the start of therapy (AUC = 0.748; 95 % CI 0.554-0.941; p = 0.0120) was observed. Survival was negatively affected by LMR 3.27 after 12-16 weeks of therapy (AUC = 0.685; 95 % CI 0.486-0.885; p = 0.0691). median survival of patients after the start of CT + TT/TT with cetuximab was 28 months (95 % CI 17-48), progression-free survival was 8 months (95 % CI 5-36). For RBC count 3.8 x 1012/L 12-16 weeks after the start of therapy, risk of progression decreased by 79 % (hazard ratio 0.21; 95 % CI 0.07-0.62; p = 0.0047). Partial response after 12-16 weeks of CT + TT/TT decreased progression risk more than 4-fold (p 0.05). The model decreasing progression-free survival includes baseline RBC ≤3.9 x 109/L, RBC ≤3.8 x 109/L after 12-16 weeks of CT + TT/TT with cetuximab and absence of partial response per the Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) (AUC = 0.792; 95 % CI 0.706-0.877; p = 0.0079).Conclusion. for prediction of CT + TT/TT with cetuximab effectiveness in patients with head and neck squamous cell carcinoma, baseline characteristics of the peripheral blood and systemic inflammation can be used. Additionally, correlations between these characteristics 12-16 weeks after the start of therapy and treatment effectiveness were observed. Increased RBC as an anemia marker can be considered an indirect mechanism of EGFR signaling pathway blocking by cetuximab through decreased level of interleukin 6, marker of systemic inflammation, and factor of chronic disease anemias hepcidin. In patients with head and neck squamous cell carcinoma, maximal effectiveness of CT + TT/TT with cetuximab requires not only therapy personalization but also anemia correction.
- Open Access
- 30 December 2023
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 13 (4) , 101-115
Risk factors for head and neck squamous cell carcinoma in disease pathogenesis and prognosis: the importance of smoking cessation and the concept of harm reduction
Introduction. Cigarette smoking along with alcohol consumption, infection with human papilloma (HPV) and the Epstein–Barr viruses, is one of the main risk factors for head and neck squamous cell carcinoma. It can also contribute to virus-associated carcinogenesis and affect the clinical and prognostic features of the tumor. Continued smoking at diagnosis of head and neck squamous cell carcinoma is a negative prognostic factor and contributes to reduced patient survival rates. Aim. To analyze the smoking status and the effect of etiopathogenesis on molecular and clinical features in patients with oropharyngeal squamous cell carcinoma (OpSCC). Materials and methods. In patients with OPSCC, the smoking status and the level of motivation to its cessation were clarified. Immunohistochemical analysis of tumor sections from paraffin blocks from the ThermoScentific immunohis-tosteiner was performed using monoclonal antibodies to estrogen receptors α (ERα), programmed death-ligand 1 (pD-L1), Bcl-2, p53 and p16. The percentage of tumor-infiltrating lymphocytes (TILs) in the stromal component of the tumor (hematoxylin and eosin staining) was also analyzed. Results. Of 113 patients with OpSCC, 80 % of patients were current smokers, including 75 % of patients with Hpv-positive tumor status. men with OpSCC were statistically significantly more likely to smoke than women (p = 0.001), as were men with Hpv-positive tumor (p = 0.015). Smoking patients were characterized by a larger size of the primary tumor (T3–4), including those with Hpv (p = 0.015). positive Hpv status of the tumor is associated with autoimmune diseases (autoimmune thyroiditis, psoriasis) (p ˂ 0.05). A high level of TILs is characteristic of smokers, including those with p16+-status (p ˂0.05), but not for all patients with this status. The positive expression of ERα is associated with p16+-status, and the latter is associated with the absence of p53 expression (p ˂0.05). During conservative therapy, tumor regression is associated with the primary tumor size T1–2, p16 + status, female sex, age less than 55 years, TILs level ≥ 57.5 %, pD-L1 expression levels on tumor cells ≥2.2 %, Bcl-2 ≥5 % and ERα ≥65 % (p ˂ 0.05). At the same time, quality of good predictive model for tumor regression showed a TILs level of ≥57.5 % (area under curve, AuC) 0.796; sensitivity 78.6 %; specificity 75 %) and ERα (AuC 0.725; sensitivity 65 %; specificity 83 %). The level of motivation to quit smoking ranged from 1 to 7 points according the 10-point motivation scale in 89 % of respondents. Only 10 patients were ready to quit smoking immediately (10 points on the motivation scale). Conclusion. Molecular heterogeneity of OPSCC was revealed, including in the group of p16+-tumors. Correlation of clinical and molecular parameters with response to conservative therapy can be used in planning of primary therapy and earlier use of surgical treatment. The level of motivation to quit smoking in patients with squamous cell carcinoma of the head and neck may be increased by drawing attention to the problem at each doctor’s appointment as well as by informing about how to quit smoking and therapeutic approaches. In unmotivated patients, the concept of reducing the harm of smoking can be used involving the replacement of cigarettes with electronic tobacco heating systems, eliminating the carcinogenic effect of its combustion products.
- 30 December 2023
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 13 (4) , 101-115
Open AccessRisk factors for head and neck squamous cell carcinoma in disease pathogenesis and prognosis: the importance of smoking cessation and the concept of harm reduction
Introduction. Cigarette smoking along with alcohol consumption, infection with human papilloma (HPV) and the Epstein–Barr viruses, is one of the main risk factors for head and neck squamous cell carcinoma. It can also contribute to virus-associated carcinogenesis and affect the clinical and prognostic features of the tumor. Continued smoking at diagnosis of head and neck squamous cell carcinoma is a negative prognostic factor and contributes to reduced patient survival rates. Aim. To analyze the smoking status and the effect of etiopathogenesis on molecular and clinical features in patients with oropharyngeal squamous cell carcinoma (OpSCC). Materials and methods. In patients with OPSCC, the smoking status and the level of motivation to its cessation were clarified. Immunohistochemical analysis of tumor sections from paraffin blocks from the ThermoScentific immunohis-tosteiner was performed using monoclonal antibodies to estrogen receptors α (ERα), programmed death-ligand 1 (pD-L1), Bcl-2, p53 and p16. The percentage of tumor-infiltrating lymphocytes (TILs) in the stromal component of the tumor (hematoxylin and eosin staining) was also analyzed. Results. Of 113 patients with OpSCC, 80 % of patients were current smokers, including 75 % of patients with Hpv-positive tumor status. men with OpSCC were statistically significantly more likely to smoke than women (p = 0.001), as were men with Hpv-positive tumor (p = 0.015). Smoking patients were characterized by a larger size of the primary tumor (T3–4), including those with Hpv (p = 0.015). positive Hpv status of the tumor is associated with autoimmune diseases (autoimmune thyroiditis, psoriasis) (p ˂ 0.05). A high level of TILs is characteristic of smokers, including those with p16+-status (p ˂0.05), but not for all patients with this status. The positive expression of ERα is associated with p16+-status, and the latter is associated with the absence of p53 expression (p ˂0.05). During conservative therapy, tumor regression is associated with the primary tumor size T1–2, p16 + status, female sex, age less than 55 years, TILs level ≥ 57.5 %, pD-L1 expression levels on tumor cells ≥2.2 %, Bcl-2 ≥5 % and ERα ≥65 % (p ˂ 0.05). At the same time, quality of good predictive model for tumor regression showed a TILs level of ≥57.5 % (area under curve, AuC) 0.796; sensitivity 78.6 %; specificity 75 %) and ERα (AuC 0.725; sensitivity 65 %; specificity 83 %). The level of motivation to quit smoking ranged from 1 to 7 points according the 10-point motivation scale in 89 % of respondents. Only 10 patients were ready to quit smoking immediately (10 points on the motivation scale). Conclusion. Molecular heterogeneity of OPSCC was revealed, including in the group of p16+-tumors. Correlation of clinical and molecular parameters with response to conservative therapy can be used in planning of primary therapy and earlier use of surgical treatment. The level of motivation to quit smoking in patients with squamous cell carcinoma of the head and neck may be increased by drawing attention to the problem at each doctor’s appointment as well as by informing about how to quit smoking and therapeutic approaches. In unmotivated patients, the concept of reducing the harm of smoking can be used involving the replacement of cigarettes with electronic tobacco heating systems, eliminating the carcinogenic effect of its combustion products.
- Open Access
- 20 December 2023
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 19 (4) , 63-74
Predictive and prognostic features of early and locally advanced PIK3CA-mutated luminal HER2-negative breast cancer
Background. Data on the prognostic role of the PIK3CA mutation in hormone receptor-positive (HR+) HER2-negative (HER2–) breast cancer (BC) are contradictory; nevertheless, there are indications of its negative predictive and prognostic significance. This dictates the need for early genetic testing of BC to predict the clinical course, select a primary therapy option and individualize systemic treatment with disease progression. Investigation of regulation of the tumor cell cycle, as well as the relationship between genetic markers, infiltration of tumor-infiltrating lymphocytes (TILs) and subpopulations of immune cells is strategically important for the search for drug therapy targets.Aim. To search for predictive and prognostic markers of the clinical course of PIK3CA-associated HR+ HER2– BC.Materials and methods. The clinical, morphological and molecular features of the tumor of 101 BC patients with PIK3CA mutations (100 women and 1 man) were analyzed. Early and locally advanced HR+ HER2– BC is present in 81 % of cases, where neoadjuvant chemotherapy (NAPCT) was performed in 28 % of patients. Primary metastatic disease was detected in 17 % of cases. An immunohistochemical evaluation was performed on sections from paraffin blocks using monoclonal antibodies to estrogen receptors, progesterone receptors, HER2, Ki-67, CD8, CD4, CD68, CD163, Bcl-2, p53, cyclin D1. TILs were evaluated when stained with hematoxylin and eosin. TILs were evaluated in the stromal component of the tumor. The correlation of clinical and morphological parameters with the type of mutation and clinical outcomes of treatment of patients with early and locally advanced HR+ HER2– BC was evaluated. The statistical analysis was performed using the IBM SPSS Statistics v. 22 statistical package.Results. In BC with the PIK3CA mutation, a low level of TILs infiltration was detected (1 point), which does not differ depending on the presence of mutations in exon 20 and exon 9 (p 0.05). However, the E545K mutation is characterized by a higher TILs level (2 points) (p = 0.05). CD4+ T-TILs and CD8+ T-TILs levels are statistically significantly higher with mutations in exon 20 compared to exon 9 of the PIK3CA gene (p = 0.017 and 0.013, respectively). At the same time, in comparison with other mutations, tumors with H1047R and E545K mutations (p = 0.05) were characterized by a higher level of CD4 and CD8 expression. Regardless of the mutated exon, a high level of CD68+ tumor-associated macrophages (Me = 80 %), was detected due to the CD163+ fraction of immunosuppressive M2-polarized tumor-associated macrophages (Me = 70 %). A feature of the regulation of the PIK3CA-mutated BC cell cycle is the high level of cyclin D1 expression, the absence of p53 expression and the positive expression of the antiapoptotic marker Bcl-2. The median disease-free survival in early and locally advanced HR+ HER2– BC with the PIK3CA mutation was 36 months (95 % confidence interval (CI) 24.720–47.280). The risk of progression was increased by NAPCT (hazard ratio 3.389; 95 % CI 1.530–7.504; p = 0.003). The risk of progression was reduced by age younger than 49 years (hazard ratio 0.54; 95 % CI 0.30–0.96, p = 0.0359) and the absence of expression of the antiapoptotic marker Bcl-2 (hazard ratio 0.36; 95 % CI 0.14–0.97; p = 0.0425).Conclusion. The data obtained indicate that BC with the PIK3CA mutation is a kind of biological subtype of HR+ HER2– BC, which shows the lack of significant efficacy of NAPCT, probably due to the immunosuppressive microenvironment and low TILs levels. At the same time, the predominant population was M2-polarized tumor-associated macrophages. Moreover, the administration of NAPCT and the positive expression of Bcl-2 reduce disease-free survival, which can be explained by the possible effect of increasing the invasiveness and migration potential of the tumor cell. It is important to continue investigation of identified clinical and morphological prognostic markers when planning and developing new strategies for the treatment of early and metastatic HR+ HER2– BC with the PIK3CA mutation, as well as the use of specific targeted therapy at early metastatic disease.
- 20 December 2023
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 19 (4) , 63-74
Open AccessPredictive and prognostic features of early and locally advanced PIK3CA-mutated luminal HER2-negative breast cancer
Background. Data on the prognostic role of the PIK3CA mutation in hormone receptor-positive (HR+) HER2-negative (HER2–) breast cancer (BC) are contradictory; nevertheless, there are indications of its negative predictive and prognostic significance. This dictates the need for early genetic testing of BC to predict the clinical course, select a primary therapy option and individualize systemic treatment with disease progression. Investigation of regulation of the tumor cell cycle, as well as the relationship between genetic markers, infiltration of tumor-infiltrating lymphocytes (TILs) and subpopulations of immune cells is strategically important for the search for drug therapy targets.Aim. To search for predictive and prognostic markers of the clinical course of PIK3CA-associated HR+ HER2– BC.Materials and methods. The clinical, morphological and molecular features of the tumor of 101 BC patients with PIK3CA mutations (100 women and 1 man) were analyzed. Early and locally advanced HR+ HER2– BC is present in 81 % of cases, where neoadjuvant chemotherapy (NAPCT) was performed in 28 % of patients. Primary metastatic disease was detected in 17 % of cases. An immunohistochemical evaluation was performed on sections from paraffin blocks using monoclonal antibodies to estrogen receptors, progesterone receptors, HER2, Ki-67, CD8, CD4, CD68, CD163, Bcl-2, p53, cyclin D1. TILs were evaluated when stained with hematoxylin and eosin. TILs were evaluated in the stromal component of the tumor. The correlation of clinical and morphological parameters with the type of mutation and clinical outcomes of treatment of patients with early and locally advanced HR+ HER2– BC was evaluated. The statistical analysis was performed using the IBM SPSS Statistics v. 22 statistical package.Results. In BC with the PIK3CA mutation, a low level of TILs infiltration was detected (1 point), which does not differ depending on the presence of mutations in exon 20 and exon 9 (p 0.05). However, the E545K mutation is characterized by a higher TILs level (2 points) (p = 0.05). CD4+ T-TILs and CD8+ T-TILs levels are statistically significantly higher with mutations in exon 20 compared to exon 9 of the PIK3CA gene (p = 0.017 and 0.013, respectively). At the same time, in comparison with other mutations, tumors with H1047R and E545K mutations (p = 0.05) were characterized by a higher level of CD4 and CD8 expression. Regardless of the mutated exon, a high level of CD68+ tumor-associated macrophages (Me = 80 %), was detected due to the CD163+ fraction of immunosuppressive M2-polarized tumor-associated macrophages (Me = 70 %). A feature of the regulation of the PIK3CA-mutated BC cell cycle is the high level of cyclin D1 expression, the absence of p53 expression and the positive expression of the antiapoptotic marker Bcl-2. The median disease-free survival in early and locally advanced HR+ HER2– BC with the PIK3CA mutation was 36 months (95 % confidence interval (CI) 24.720–47.280). The risk of progression was increased by NAPCT (hazard ratio 3.389; 95 % CI 1.530–7.504; p = 0.003). The risk of progression was reduced by age younger than 49 years (hazard ratio 0.54; 95 % CI 0.30–0.96, p = 0.0359) and the absence of expression of the antiapoptotic marker Bcl-2 (hazard ratio 0.36; 95 % CI 0.14–0.97; p = 0.0425).Conclusion. The data obtained indicate that BC with the PIK3CA mutation is a kind of biological subtype of HR+ HER2– BC, which shows the lack of significant efficacy of NAPCT, probably due to the immunosuppressive microenvironment and low TILs levels. At the same time, the predominant population was M2-polarized tumor-associated macrophages. Moreover, the administration of NAPCT and the positive expression of Bcl-2 reduce disease-free survival, which can be explained by the possible effect of increasing the invasiveness and migration potential of the tumor cell. It is important to continue investigation of identified clinical and morphological prognostic markers when planning and developing new strategies for the treatment of early and metastatic HR+ HER2– BC with the PIK3CA mutation, as well as the use of specific targeted therapy at early metastatic disease.
- Open Access
- 27 June 2022
- Published by Scientific Research Institute - Ochapovsky Regional Clinical Hospital No 1 in Innovative Medicine of Kuban
- No. 2,p. 85-92
The epithelial-to-mesenchymal transition in cancer: pathogenetic features
The epithelial‑to‑mesenchymal transition (EMT) is a cellular biological process, that occurs in a wide range of cells and tissues and is triggered by complex regulatory networks involving transcriptional control with SNAIL, ZEB1, ZEB2, Twist, SLUG, E‑cadherin, vimentin, tumor microenvironment and genetic characteristics. EMT is represented by the multi‑stage development and transformation of cells of the epithelial phenotype into cells that acquire mesenchymal features of various severity. These quasi‑mesenchymal cells are characterized by stemness, tumor heterogeneity, increasing invasiveness, drug resistance and a tendency to distant metastasis, which leads to the proliferation of neoplastic cells, tumor dissemination and initiation of metastasis, which induces the therapy resistance and the oncological recurrence.This review is based on the latest scientific publications about the EMT phenomenon, indexed in PubMed. The aim of the study was to evaluate the biochemical and molecular pathogenetic mechanisms of EMT and the effect of EMT markers on the progression of neoplastic processes and the effectiveness of the treatment. Nowadays the proper EMT scheme that combines all the molecular transformations of sells with quasi‑mesenchymal phenotype doesn’t exist. But analyzing the features of this cellular program, we can find the proper therapy, that could be able to suppress the plasticity of cancer cells, prevent EMT induction by blocking contextual signals, and induce mesenchymal‑epithelial transition. All these aspects will lead to the reduction of the risk of tumor dissemination and the increase of the effectiveness of cancer treatment.
- 27 June 2022
- Published by Scientific Research Institute - Ochapovsky Regional Clinical Hospital No 1 in Innovative Medicine of Kuban
- No. 2,p. 85-92
Open AccessThe epithelial-to-mesenchymal transition in cancer: pathogenetic features
The epithelial‑to‑mesenchymal transition (EMT) is a cellular biological process, that occurs in a wide range of cells and tissues and is triggered by complex regulatory networks involving transcriptional control with SNAIL, ZEB1, ZEB2, Twist, SLUG, E‑cadherin, vimentin, tumor microenvironment and genetic characteristics. EMT is represented by the multi‑stage development and transformation of cells of the epithelial phenotype into cells that acquire mesenchymal features of various severity. These quasi‑mesenchymal cells are characterized by stemness, tumor heterogeneity, increasing invasiveness, drug resistance and a tendency to distant metastasis, which leads to the proliferation of neoplastic cells, tumor dissemination and initiation of metastasis, which induces the therapy resistance and the oncological recurrence.This review is based on the latest scientific publications about the EMT phenomenon, indexed in PubMed. The aim of the study was to evaluate the biochemical and molecular pathogenetic mechanisms of EMT and the effect of EMT markers on the progression of neoplastic processes and the effectiveness of the treatment. Nowadays the proper EMT scheme that combines all the molecular transformations of sells with quasi‑mesenchymal phenotype doesn’t exist. But analyzing the features of this cellular program, we can find the proper therapy, that could be able to suppress the plasticity of cancer cells, prevent EMT induction by blocking contextual signals, and induce mesenchymal‑epithelial transition. All these aspects will lead to the reduction of the risk of tumor dissemination and the increase of the effectiveness of cancer treatment.
- Open Access
- 15 April 2022
- Published by Siberian State Medical University in Bulletin of Siberian Medicine
- Vol. 21 (1) , 171-182-182
Dynamic changes in the tumor microenvironment under the effect of estradiol as a diagnostic tool and target for targeted cancer therapy
Activation of the estrogen receptor-α (ER-α) signaling pathway is a significant factor in the initiation of carcinogenesis in various types of tumors due to the genomic and non-genomic effects of estradiol in cancer cells. However, data on the expression of ER-α and aromatase on stromal and immune cells in the tumor microenvironment (TME) point to an additional mechanism by which estrogens increase tumor malignancy. There is growing evidence that TME can affect tumor immunity by increasing the immune response or reducing immunoreactivity.The important role of estrogen and the estrogen receptor signaling pathway in the response of the tumor microenvironment in cancer of various localizations, not only classical hormone-dependent cancers, has been proven. However, the clinical effectiveness of blocking the effect of estrogen on tumor growth has been primarily shown in cancer of the female reproductive system. At the same time, data on the significant role of TME in the development of endocrinotherapy resistance in breast cancer treatment are of great interest.Despite the possibilities of standard therapy, a more in-depth study on the role of various TME components in cancer evolution, creation of a micrometastatic niche, as well as in the response to therapy may result in development of new strategies for cancer treatment. It is also necessary to study the possibilities of overcoming the immunosuppressive effect of the estrogen receptor signaling pathway on TME in order to increase the survival rates in patients with hormone-dependent cancers, particularly, breast cancer.
- 15 April 2022
- Published by Siberian State Medical University in Bulletin of Siberian Medicine
- Vol. 21 (1) , 171-182-182
Open AccessDynamic changes in the tumor microenvironment under the effect of estradiol as a diagnostic tool and target for targeted cancer therapy
Activation of the estrogen receptor-α (ER-α) signaling pathway is a significant factor in the initiation of carcinogenesis in various types of tumors due to the genomic and non-genomic effects of estradiol in cancer cells. However, data on the expression of ER-α and aromatase on stromal and immune cells in the tumor microenvironment (TME) point to an additional mechanism by which estrogens increase tumor malignancy. There is growing evidence that TME can affect tumor immunity by increasing the immune response or reducing immunoreactivity.The important role of estrogen and the estrogen receptor signaling pathway in the response of the tumor microenvironment in cancer of various localizations, not only classical hormone-dependent cancers, has been proven. However, the clinical effectiveness of blocking the effect of estrogen on tumor growth has been primarily shown in cancer of the female reproductive system. At the same time, data on the significant role of TME in the development of endocrinotherapy resistance in breast cancer treatment are of great interest.Despite the possibilities of standard therapy, a more in-depth study on the role of various TME components in cancer evolution, creation of a micrometastatic niche, as well as in the response to therapy may result in development of new strategies for cancer treatment. It is also necessary to study the possibilities of overcoming the immunosuppressive effect of the estrogen receptor signaling pathway on TME in order to increase the survival rates in patients with hormone-dependent cancers, particularly, breast cancer.
- Open Access
- 23 September 2021
- Published by Scientific Research Institute - Ochapovsky Regional Clinical Hospital No 1 in Innovative Medicine of Kuban
- No. 3,p. 57-63
Liquid biopsy: the current state of the issue
Background Liquid biopsy is a promising method of diagnosing malignant tumors. It allows determining the level of free circulating tumor cells – micrometastases, tumor DNA, microRNA and exosomes in blood plasma, as well as detecting various genetic changes. This work included a literature review of current scientific publications on liquid biopsy techniques indexed in PubMed.Objective The aim of the study was to evaluate the efficacy and peculiarities of this technique in comparison with standard methods of morphological verification of oncological diseases, as well as the feasibility of its use in clinical practice. Compared to tissue biopsy LB has the following advantages: simplicity and speed of examination, easy repeatability and low invasiveness, possibility of dynamic monitoring of tumor progression – general clonal transformation as well as the appearance of resistance to treatment. The disadvantages of this method include low sensitivity, difficulty in proper interpretation of biomarkers and determination of their specificity, high risk of false positive and false negative results due to the presence of dormant tumor cells.Conclusion Currently, liquid biopsy analysis in clinical practice requires standardization and continuous validation.
- 23 September 2021
- Published by Scientific Research Institute - Ochapovsky Regional Clinical Hospital No 1 in Innovative Medicine of Kuban
- No. 3,p. 57-63
Open AccessLiquid biopsy: the current state of the issue
Background Liquid biopsy is a promising method of diagnosing malignant tumors. It allows determining the level of free circulating tumor cells – micrometastases, tumor DNA, microRNA and exosomes in blood plasma, as well as detecting various genetic changes. This work included a literature review of current scientific publications on liquid biopsy techniques indexed in PubMed.Objective The aim of the study was to evaluate the efficacy and peculiarities of this technique in comparison with standard methods of morphological verification of oncological diseases, as well as the feasibility of its use in clinical practice. Compared to tissue biopsy LB has the following advantages: simplicity and speed of examination, easy repeatability and low invasiveness, possibility of dynamic monitoring of tumor progression – general clonal transformation as well as the appearance of resistance to treatment. The disadvantages of this method include low sensitivity, difficulty in proper interpretation of biomarkers and determination of their specificity, high risk of false positive and false negative results due to the presence of dormant tumor cells.Conclusion Currently, liquid biopsy analysis in clinical practice requires standardization and continuous validation.